Skip to content
Screener

Penumbra PEN Cash & Equivalents

Cash & Equivalents at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Stryker logo
StrykerSYK
$3.39B+42.8%
AngioDynamics logo
AngioDynamicsANGO
$53.86M-3.6%
Medtronic logo
MedtronicMDT
$1.95B-12.1%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$488.08M+23.4%
TFX
TeleflexTFX
$316.92M+23.5%

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.73B+36.0%
Enterprise value$12.71B+38.7%
P/E74.4×+11.1×
P/S8.8×+1.4×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio6×-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Penumbra’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001321732-26-000019
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Effect of foreign exchange rate changes on cash and cash equivalents(39)474
NET INCREASE IN CASH AND CASH EQUIVALENTS54,39251,650
CASH AND CASH EQUIVALENTS—Beginning of period186,897324,404
CASH AND CASH EQUIVALENTS—End of period$241,289$376,054
NONCASH INVESTING AND FINANCING ACTIVITIES:
Right-of-use assets obtained in exchange for operating lease obligations$486$838
Right-of-use assets obtained in exchange for finance lease obligations$118$7
Purchase of property and equipment funded through accounts payable and accrued liabilities$11,779$1,727

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Penumbra's cash & equivalents?
Penumbra (PEN) reported cash & equivalents of $241.29M in Q1 2026.
How has Penumbra's cash & equivalents changed year-over-year?
Penumbra's cash & equivalents decreased by 35.8% year-over-year, from $376.05M to $241.29M.
What is the long-term trend for Penumbra's cash & equivalents?
Over 5 years (2020 to 2025), Penumbra's cash & equivalents has grown at a 21.8% compound annual growth rate (CAGR), from $69.67M to $186.9M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Penumbra's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude